-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: keymaster@town.hall.org Originator-Key-Asymmetric: MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ== MIC-Info: RSA-MD5,RSA, Foxp54/6fg2qcWyigBz6FRo/sw7Xm42O7GfxMJAwt1d3aXtJrZAbl0NdyV2MbfIB cpY3a+m2joII6IaUsi5rpQ== 0000950123-94-001370.txt : 19940822 0000950123-94-001370.hdr.sgml : 19940822 ACCESSION NUMBER: 0000950123-94-001370 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19940816 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 19940817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERCK & CO INC CENTRAL INDEX KEY: 0000064978 STANDARD INDUSTRIAL CLASSIFICATION: 2834 IRS NUMBER: 221109110 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03305 FILM NUMBER: 94544734 BUSINESS ADDRESS: STREET 1: ONE MERCK DR STREET 2: P O BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 9084231000 MAIL ADDRESS: STREET 1: ONE MERCK DR STREET 2: PO BOX 100 WS3AB-05 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 8-K 1 MERCK & CO., INC. 1 SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 1994 ----------------- MERCK & CO., Inc. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) New Jersey - -------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 1-3305 22-1109110 - --------------------------- ---------------------------------------------- (Commission File Number) (IRS Employer Identification No.) One Merck Drive, PO Box 100, Whitehouse Station, NJ 08889-0100 - -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (908)423-1000 ----------------- 2 Item 5. Other Events Incorporated by reference is a press release issued by the Registrant on August 16, 1994, attached as Exhibit 99, providing information concerning the Registrant's announcement of its intention to sell its specialty chemical units, Kelco and Calgon Vestal Laboratories. The decision to sell reflects the Registrant's intention to focus its resources on its integrated pharmaceutical and pharmacy benefits management business. Item 7. Financial Statements and Exhibits (c) Exhibit Exhibit 99 - Press release issued August 16, 1994. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. MERCK & CO., Inc. By: /s/ Nancy V. Van Allen ---------------------- Nancy V. Van Allen Assistant Secretary August 17, 1994 3 EXHIBIT INDEX
Exhibit Number Description - ------- ----------- 99 Press release issued August 16, 1994
EX-99 2 PRESS RELEASE 1 EXHIBIT 99 FOR IMMEDIATE RELEASE Press Contacts: John Doorley Office: (908) 423-4081 Home: (908) 232-2052 Investor Contact: Jim Hinrichs Office: (908) 423-6883 Whitehouse Station, N.J. August 16, 1994 -- Merck & Co., Inc. announced today its intention to sell its specialty chemical units, Kelco and Calgon Vestal Laboratories. The decision was made despite the fact that the operating performances of both Kelco and Calgon Vestal have been and continue to be excellent. Merck President and CEO Ray Gilmartin said that the decision reflects the Company's intention to focus its resources on its integrated pharmaceutical and pharmacy benefits management business. "We believe that by concentrating our resources on these areas, we can remain a research-driven, premier-growth company, even in the face of the challenging market conditions and government pressures on the pharmaceutical industry," Mr. Gilmartin said. "By remaining a premier-growth company, one whose performance puts it in the top tier of U.S. companies, Merck can continue to fund the innovative research that serves patients, physicians, customers and society." Over the coming weeks, Merck and J.P. Morgan Securities Inc., which is assisting in the sales, will contact a limited number of prospective buyers and begin a process that will lead to negotiations and the sale of the businesses. Merck anticipates that this process will be completed by the end of the year. Merck hopes to find buyers with strategic interests in focusing on the continued growth and success of Kelco's and Calgon Vestal's businesses. 2 Kelco is a world leader in the development, application and production of alginates and biogums used in applications such as health care, food processing, oil exploration, paper, textiles and personal care. Kelco, headquartered in San Diego, Calif., has approximately 1,300 employees. Calgon Vestal is a leading wound management, skin care and infection-control business headquartered in St. Louis, Mo., with about 700 employees. Merck & Co., Inc., is a worldwide research-intensive company that discovers, develops, produces and markets human and animal health products. Its Medco unit is the leading pharmacy benefits management company. Merck is headquartered in Whitehouse Station, N.J., and invested more than $1.2 billion last year in pharmaceutical research and development. ### -----END PRIVACY-ENHANCED MESSAGE-----